Ivermectin Substipharm

Ivermectin, the active ingredient in Ivermectin Substipharm, is an anthelmintic presented as an oral formulation for oral use. It is employed to treat a range of parasitic worm infections and ectoparasitic conditions in humans. The drug targets specific parasites, helping to eliminate infection and reduce disease transmission.

GNH USA supplies Ivermectin Substipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable access to quality‑assured medicines across multiple regions.

Ivermectin is an anthelmintic used to treat infections caused by various helminths and ectoparasites.

Onchocerciasis: reduces microfilarial load and prevents disease progression. Strongyloidiasis: eradicates intestinal larvae and prevents hyperinfection. Scabies: eliminates the Sarcoptes mite, relieving itching and skin lesions. Lymphatic filariasis: lowers circulating filarial worms, aiding control programs. Other helminth infections: provides broad‑spectrum activity against multiple nematodes.

Ivermectin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Dizziness - Diarrhea

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or severe skin rash - Hepatic injury - Anaphylactic reaction

Use of Ivermectin requires careful consideration of patient‑specific factors. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown; consider potential exposure to infant. - Renal impairment: use with caution and monitor renal function. - Hepatic impairment: dose adjustment may be required; monitor liver enzymes. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep in original container, protect from moisture and light.

Ivermectin can interact with several drug classes, necessitating monitoring.

Major Interactions (Avoid): - Co‑administration with strong CYP3A4 inducers (e.g., rifampicin) may reduce efficacy. - Concurrent use with P‑glycoprotein inhibitors (e.g., verapamil) can increase plasma levels.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Macrolide antibiotics: potential increase in ivermectin exposure; observe for toxicity. - Anticonvulsants: may alter seizure threshold; assess clinical response.